The move follows similar initiatives by players like Syngene, Laurus Labs, and Aragen. Industry analysts see Bharat Biotech’s ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Novo Nordisk made a much higher offer to acquire a biotech Pfizer was already set to buy out. Losing this battle would be more damaging to Pfizer than to Novo Nordisk. Even so, both companies look ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Dr. Vinay Prasad, who oversees FDA’s vaccine and biologics center, resigned in July after coming under fire from conservative ...

Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb in a cancer immunotherapy alliance that seeks to challenge ...

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine.

Krystal Biotech Inc. advanced stock charts by Barron's. View KRYS historical stock data and compare to other stocks, and exchanges.

Vertex Pharmaceuticals (VRTX) is rapidly closing the market capitalization gap with pharmaceutical behemoth Pfizer (PFE), leveraging a robust growth trajectory and a diversified pipeline that ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!

Synthetic biology is ready for the next developmental milestone and America’s leadership depends on getting the financing right.